PT  - JOURNAL ARTICLE
AU  - Kim, Jihye
AU  - Kim, Ju Yeon
AU  - Lee, Jeong-Hoon
AU  - Sinn, Dong Hyun
AU  - Hur, Moon Haeng
AU  - Hong, Ji Hoon
AU  - Park, Min Kyung
AU  - Cho, Hee Jin
AU  - Choi, Na Ryung
AU  - Lee, Yun Bin
AU  - Cho, Eun Ju
AU  - Yu, Su Jong
AU  - Kim, Yoon Jun
AU  - Paeng, Jin Chul
AU  - Kim, Hyo Cheol
AU  - Yi, Nam-Joon
AU  - Lee, Kwang-Woong
AU  - Suh, Kyung-Suk
AU  - Hyun, Dongho
AU  - Kim, Jong Man
AU  - Yoon, Jung-Hwan
TI  - Long-Term Outcomes of Transarterial Radioembolization for Large Single Hepatocellular Carcinoma: A Comparison to Resection
AID  - 10.2967/jnumed.121.263147
DP  - 2022 Aug 01
TA  - Journal of Nuclear Medicine
PG  - 1215--1222
VI  - 63
IP  - 8
4099  - http://jnm.snmjournals.org/content/63/8/1215.short
4100  - http://jnm.snmjournals.org/content/63/8/1215.full
SO  - J Nucl Med2022 Aug 01; 63
AB  - The surgical treatment for large hepatocellular carcinoma (HCC) remains controversial because of a high risk of recurrence after resection. This study aimed to compare long-term outcomes of transarterial radioembolization (TARE) with resection for patients with large HCC. Methods: This retrospective cohort study included 557 patients who were initially treated with either resection (n = 500) or TARE (n = 57) for large (≥5 cm), single nodular HCC at 2 tertiary centers in Korea. Patients with major portal vein tumor thrombosis or extrahepatic metastasis were excluded. The primary endpoint was overall survival (OS), and secondary endpoints were time to progression (TTP), time to intrahepatic progression (TTIP), and safety. Results: The resection group was younger (median, 60 vs. 69 y) and had a smaller tumor size (median, 7.0 vs. 10.0 cm) (all P < 0.05). After baseline characteristics were balanced using inverse-probability-of-treatment weighting, the OS (hazard ratio [HR], 0.98; 95% CI, 0.40–2.43; P = 0.97), TTP (HR, 1.10; 95% CI, 0.55–2.20; P = 0.80), and TTIP (HR, 1.45; 95% CI, 0.72–2.93; P = 0.30) of the TARE group was comparable to the resection group. TARE was not an independent risk for OS (adjusted HR, 1.04; 95% CI, 0.42–2.59; P = 0.93), TTP (adjusted HR, 0.98; 95% CI, 0.50–1.95; P = 0.96), or TTIP (adjusted HR, 1.30; 95% CI, 0.65–2.58; P = 0.46). The TARE group had a shorter hospital stay and fewer adverse events than the resection group. Conclusion: Compared with surgical resection for large single nodular HCC, TARE showed a comparable OS, TTP, and TTIP and a better safety profile.